Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis.

Han YangNan LiYoulian ZhouZhilan XiaoHaoming Tian Ming Hu Sheyu Li

Published in: Drug design, development and therapy (2020)

Adding ezetimibe to the moderate-dose statin in secondary prevention for CVD is cost-effective, compared with the high-dose statin in the Chinese context whose low-density lipoprotein cholesterol (LDL-c) was not inadequately controlled by moderate-dose statin alone.

Keyphrases

high dose
cardiovascular disease
high intensity
coronary artery disease
low dose
low density lipoprotein
stem cell transplantation
type diabetes
metabolic syndrome
cardiovascular risk factors